A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)

A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)

Abstract Background The safety information of netarsudil primarily comes from clinical trials experience. This study aimed to explore the ocular and systemic safety of netarsudil through data mining the FDA Adverse Event Reporting System (FAERS) database. Methods Adverse event (AE) reports submitted...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaomei Xiong, Xiuwen Zhang, Fengmin Tang, Taomin Huang
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Pharmacology and Toxicology
Subjects:
Adverse event
FAERS
Glaucoma
Netarsudil
Pharmacovigilance
Online Access:https://doi.org/10.1186/s40360-025-00927-x
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items